TMCnet News

ArcherDX Releases New Version of Assay Analysis Software with Archer™ Analysis Version 3.2
[May 22, 2015]

ArcherDX Releases New Version of Assay Analysis Software with Archer™ Analysis Version 3.2


ArcherDX today launched a new version of Archer™ Analysis, the company's bioinformatics platform (http://archerdx.com/software/analysis). Archer Analysis supports automated sequence analysis and mutation detection from libraries created using Archer™ FusionPlex™ RNA-based sequencing assays. The newest release, Analysis 3.2, now supports analysis for libraries created from the forthcoming Archer VariantPlex™ DNA sequencing assays. "Combining RNA-based fusion detection with DNA-based SNP and copy number analysis gives you a better understanding of the driver mutations in tumor samples," states Jason Myers, CEO of ArcherDX. "Building out analysis software designed specifically for our enrichment chemistry allows our customers to take full advantage of the inherent benefits of Anchored Multiplex PCR (News - Alert)."

The newest version of Archer Analysis provides mutation detection and reporting for somtic and germline mutations and copy number variations, along with gene fusions, SNPs and indels. Analysis 3.2 is integrated with the Archer Quiver™ Fusion Database (http://quiver.archerdx.com/), a mutation database of all published gene translocations. In addition to analyzing sequencing files, Analysis 3.2 also incorporates mutation visualization, variant effect prediction, variant annotation and the ability to create printable analysis reports.



About ArcherDX

ArcherDX addresses the bottlenecks associated with using next-generation sequencing (NGS) in translational research by offering a robust platform for targeted sequencing applications. By combining proprietary Anchored Multiplexed PCR (AMP) chemistry and easy-to-use, lyophilized reagents, Archer™ technology generates highly enriched sequencing libraries for genetic analysis via NGS.


Archer FusionPlex™ assays take advantage of unique features of AMP chemistry in order to identify known and novel gene fusions from FFPE and other clinical sample types. Complemented by the Archer Analysis suite of bioinformatics and reporting software, ArcherDX technology dramatically enhances complex mutation identification and discovery.

ArcherDX is headquartered in Boulder, CO, with manufacturing operations in Beverly, MA.

Archer kits and analysis software are for research use only and not for use in diagnostic procedures.

http://archerdx.com


[ Back To TMCnet.com's Homepage ]